NKX2-1 and neoplasm: The fact that survival varied from 12 to 36 weeks in non-induced Nkx2.1-CreERT2;BrafCA/+mice (Figure 4D and Table S1B) suggested that asynchronous tumor development conferred a wide spectrum of phenotypes and outcomes that might relate to different onset of growth and progression of individual tumors.